| abstract |
HKAFE42 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HKAFE42 polypeptides and polynucleotides in the design of protocols for the treatment of disorders of the central nervous system (including anxiety, depression, schizophrenia and Parkinson's disease), muscle diseases (including muscular dystrophies and multiple sclerosis), Alzheimer's disease, hematopoetic disorders, allergic diseases, autoimmune diseases, immunodeficiency and cancer, among others, and diagnostic assays for such conditions. |